Genzyme Sues Seikagaku Over Synvisc-One Patent

Law360, New York (April 14, 2011, 5:47 PM EDT) -- Genzyme Corp. sued Seikagaku Corp. in Massachusetts on Thursday, claiming the Japanese pharmaceutical company's newly approved treatment for osteoarthritis knee pain infringes a patent for its knee pain relief treatment Synvisc-One.

The suit, filed in the U.S. District Court for the District of Massachusetts, alleges that Seikagaku's hyaluronic acid-based  Gel-One infringes U.S. Patent Number 5,399,351, titled "Biocompatible Viscoelastic Gel Slurries, Their Preparation and Use," issued March 21, 1995, by the U.S. Patent and Trademark Office.

Gel-One, a single-injection pain relief treatment, was approved March 22 by...
To view the full article, register now.